Clinical Trials Directory
We are doing this study to learn more about prostate cancer and whether certain treatments are related with different outcomes and patient experiences.
We are doing this study to find out if an experimental drug combination made up of ivosidenib, gemcitabine, cisplatin, and durvalumab is a safe and effective for treating cholangiocarcinoma.
This study has 3 parts: 1. Screening - Lasts up to 28 days. You'll get heart tests, scans, and blood and urine tests. 2. Treatment - You'll be randomly picked to get either a new medicine (iza-bren) or a cancer medicine your doctor chooses. You'll visit the clinic 2-3 times every few weeks. 3. Follow-up - After treatment ends, you'll have: - A safety check 30 days later - Regular checkups every 12 weeks - More tests like scans and heart checks
We are doing this study to find out if the drugs talquetamab and teclistamab are a safe and effective option for people with multiple myeloma that has come back after treatment (relapsed) or is not improving with treatment (refractory).
We are doing this study to find out if the study drug JCAR017 is safe and to find out what dose is recommended for patients with relapsed/refractory CLL or SLL.
We are doing this study to evaluate the outcomes of patellar instability treatments at Duke. We want to learn more about how people do over time after they have chosen surgical or non-surgical options for treatment. We want to evaluate several lifestyle factors after treatment, including return to activities, pain, or any need for additional treatment or surgery.
We are doing this study is to evaluate the outcomes of medial patellofemoral ligament (MPFL) reconstruction surgery. This surgery is a common treatment for recurrent patellofemoral instability. We want to find out what factors most influence the likelihood of this procedure being successful.
We are doing this study to find out if an experimental drug called KTX-1001 (the study drug) is a safe and effective treatment for multiple myeloma. We want to identify the most appropriate dose and dosing schedule of the study drug for patients with multiple myeloma.